Published in Eur Heart J on February 08, 2007
Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev (2012) 1.06
Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol (2011) 1.05
A biomarker panel for peripheral arterial disease. Vasc Med (2008) 1.01
Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail (2012) 0.97
Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev (2012) 0.96
BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev (2014) 0.90
Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. Atherosclerosis (2011) 0.88
Biomarkers for chronic heart failure : diagnostic, prognostic, and therapeutic challenges. Herz (2009) 0.85
Novel biomarkers for contrast-induced acute kidney injury. Biomed Res Int (2014) 0.84
Can we prevent or treat renal dysfunction in acute heart failure? Heart Fail Rev (2012) 0.83
Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents. Heart Vessels (2015) 0.82
Current and novel renal biomarkers in heart failure. Heart Fail Rev (2012) 0.81
Improving prognosis estimation in patients with heart failure and the cardiorenal syndrome. Int J Nephrol (2011) 0.81
Novel renal biomarkers to assess cardiorenal syndrome. Curr Heart Fail Rep (2014) 0.80
Limited value of cystatin-C over estimated glomerular filtration rate for heart failure risk stratification. PLoS One (2012) 0.79
Incorporating common biomarkers into the clinical management of heart failure. Curr Heart Fail Rep (2013) 0.78
Cystatin C, N-terminal probrain natriuretic peptides and outcomes in acute heart failure with acute kidney injury in a 12-month follow-up: Insights into the cardiorenal syndrome. J Res Med Sci (2014) 0.77
Cardiorenal Syndrome Type 1: Renal Dysfunction in Acute Decompensated Heart Failure. J Clin Outcomes Manag (2015) 0.77
Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome. Expert Rev Cardiovasc Ther (2012) 0.76
Assessment of Serum Cystatin C Levels in Newly Diagnosed Acute Myocardial Infarction at the Onset and at the Time of Hospital Discharge. Cardiol Res (2015) 0.75
Prognostic indicators of patients with acute kidney injury in intensive care unit. World J Emerg Med (2010) 0.75
Ventricular conduction abnormalities as predictors of long-term survival in acute de novo and decompensated chronic heart failure. ESC Heart Fail (2015) 0.75
Differential prognostic utility of NTproBNP and Cystatin C in patients with acute exacerbation of chronic pulmonary disease. JRSM Short Rep (2010) 0.75
Chronic Heart Failure and Comorbid Renal Dysfunction - A Focus on Type 2 Cardiorenal Syndrome. Curr Cardiol Rev (2016) 0.75
Biomarkers in heart failure: a clinical review. Heart Fail Rev (2008) 0.75
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet (2010) 6.07
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA (2004) 3.88
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA (2004) 3.68
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA (2007) 2.90
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J (2008) 2.65
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation (2004) 2.56
Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med (2007) 2.44
Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation (2003) 2.31
International perspectives on emergency department crowding. Acad Emerg Med (2011) 2.29
Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24
Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: the Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: a randomized, controlled trial. Am Heart J (2006) 2.19
Diabetes and depression? Secular trends in the use of antidepressants among persons with diabetes in Finland in 1997-2007. Pharmacoepidemiol Drug Saf (2010) 2.12
Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr (2012) 2.10
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med (2003) 2.09
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA (2006) 2.00
Community mental-health services and suicide rate in Finland: a nationwide small-area analysis. Lancet (2008) 1.86
Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J (2008) 1.81
Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J (2006) 1.80
A novel mutation, Ser143Pro, in the lamin A/C gene is common in finnish patients with familial dilated cardiomyopathy. Eur Heart J (2004) 1.78
Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol (2009) 1.76
Evidence-based use of levosimendan in different clinical settings. Eur Heart J (2006) 1.73
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium. Eur J Emerg Med (2013) 1.71
Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol (2013) 1.69
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens (2002) 1.69
Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. J Hypertens (2003) 1.69
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J (2015) 1.68
Predictive value of electrocardiographic QT interval and T-wave morphology parameters for all-cause and cardiovascular mortality in a general population sample. Heart Rhythm (2009) 1.68
Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care (2010) 1.67
Expression of heme oxygenase-1 in response to myocardial infarction in rats. J Mol Cell Cardiol (2002) 1.66
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol (2003) 1.65
Coronary artery disease-associated locus on chromosome 9p21 and early markers of atherosclerosis. Arterioscler Thromb Vasc Biol (2008) 1.62
Relationship of common candidate gene variants to electrocardiographic T-wave peak to T-wave end interval and T-wave morphology parameters. Heart Rhythm (2010) 1.58
Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail (2015) 1.56
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol (2008) 1.56
Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry (2013) 1.55
Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol (2013) 1.55
Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart (2012) 1.54
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens (2004) 1.53
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension (2004) 1.52
Genetics of dilated cardiomyopathy. Ann Med (2007) 1.52
Amputations and socioeconomic position among persons with diabetes mellitus, a population-based register study. BMJ Open (2013) 1.51
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens (2002) 1.51
Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology (2006) 1.50
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension (2005) 1.49
Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. Clin Chem (2005) 1.48
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens (2009) 1.48
Early familial dilated cardiomyopathy: identification with determination of disease state parameter from cine MR image data. Radiology (2008) 1.48
Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail (2010) 1.46
Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens (2008) 1.46
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia (2014) 1.46
Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. Crit Care Med (2011) 1.45
Cemented or uncemented hemiarthroplasty for the treatment of femoral neck fractures? Acta Orthop (2014) 1.45
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens (2008) 1.44
Quantifying cardiac hemodynamic stress and cardiomyocyte damage in ischemic and nonischemic acute heart failure. Circ Heart Fail (2011) 1.44
Coronary heart disease: from a disease of middle-aged men in the late 1970s to a disease of elderly women in the 2000s. Eur Heart J (2005) 1.44
Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodies. Clin Chem (2005) 1.43
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation (2007) 1.41
Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens (2016) 1.41
Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens (2006) 1.39
Magnetocardiographic indices of left ventricular hypertrophy. J Hypertens (2002) 1.38
Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin Chem (2008) 1.37
Risk of multiple reoperations after lumbar discectomy: a population-based study. Spine (Phila Pa 1976) (2003) 1.33
Fewer major amputations among individuals with diabetes in Finland in 1997-2007: a population-based study. Diabetes Care (2010) 1.28
Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail (2009) 1.25
QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension (2004) 1.25
Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J (2004) 1.21
Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens (2002) 1.21